X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DIVIS LABORATORIES NATCO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 13.4 35.3 38.1% View Chart
P/BV x 3.8 6.9 56.0% View Chart
Dividend Yield % 1.2 0.7 177.4%  

Financials

 NATCO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
NATCO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0801,142 94.6%   
Low Rs671533 125.9%   
Sales per share (Unadj.) Rs592.1146.6 403.9%  
Earnings per share (Unadj.) Rs188.433.0 570.3%  
Cash flow per share (Unadj.) Rs206.338.4 537.3%  
Dividends per share (Unadj.) Rs8.2510.00 82.5%  
Dividend yield (eoy) %0.91.2 78.9%  
Book value per share (Unadj.) Rs833.6222.8 374.1%  
Shares outstanding (eoy) m36.90265.47 13.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.55.7 25.9%   
Avg P/E ratio x4.625.3 18.3%  
P/CF ratio (eoy) x4.221.8 19.5%  
Price / Book Value ratio x1.13.8 28.0%  
Dividend payout %4.430.3 14.5%   
Avg Mkt Cap Rs m32,311222,318 14.5%   
No. of employees `0004.810.8 44.9%   
Total wages/salary Rs m3,2564,561 71.4%   
Avg. sales/employee Rs Th4,522.53,616.0 125.1%   
Avg. wages/employee Rs Th674.0423.8 159.0%   
Avg. net profit/employee Rs Th1,439.0814.9 176.6%   
INCOME DATA
Net Sales Rs m21,84838,915 56.1%  
Other income Rs m4041,134 35.6%   
Total revenues Rs m22,25240,049 55.6%   
Gross profit Rs m9,28412,617 73.6%  
Depreciation Rs m6621,425 46.5%   
Interest Rs m15413 1,157.9%   
Profit before tax Rs m8,87212,313 72.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9203,543 54.2%   
Profit after tax Rs m6,9528,770 79.3%  
Gross profit margin %42.532.4 131.1%  
Effective tax rate %21.628.8 75.2%   
Net profit margin %31.822.5 141.2%  
BALANCE SHEET DATA
Current assets Rs m21,30745,351 47.0%   
Current liabilities Rs m5,9206,507 91.0%   
Net working cap to sales %70.499.8 70.6%  
Current ratio x3.67.0 51.6%  
Inventory Days Days73127 57.8%  
Debtors Days Days10795 111.9%  
Net fixed assets Rs m14,98621,160 70.8%   
Share capital Rs m369531 69.5%   
"Free" reserves Rs m30,35358,625 51.8%   
Net worth Rs m30,76059,156 52.0%   
Long term debt Rs m00-   
Total assets Rs m37,15167,832 54.8%  
Interest coverage x58.6926.8 6.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.6 102.5%   
Return on assets %19.112.9 147.7%  
Return on equity %22.614.8 152.4%  
Return on capital %29.320.8 140.8%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m10,32232,359 31.9%   
Fx outflow Rs m2,9789,042 32.9%   
Net fx Rs m7,34323,317 31.5%   
CASH FLOW
From Operations Rs m4,6367,759 59.8%  
From Investments Rs m-11,155-4,783 233.2%  
From Financial Activity Rs m6,509-3,142 -207.2%  
Net Cashflow Rs m-18-166 10.8%  

Share Holding

Indian Promoters % 52.0 52.0 100.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.8 66.4%  
FIIs % 16.6 19.0 87.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.2 151.2%  
Shareholders   25,395 31,796 79.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  MERCK LTD  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 12, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS